search
Back to results

Clinical Study on the Efficacy of Natural Stem Cell Mobilizers on Parkinson Disease

Primary Purpose

Parkinson Disease

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
StemRegen product
Sponsored by
Sociedad Española de Medicina Regenerativa y Terapia Celular
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease

Eligibility Criteria

21 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adults from both genders Diagnosed by neurologist or qualified health care practitioner with PD for 5 years or more Stabilized symptomatic treatment for PD for more than 3 months Age: over 21 years old Volunteers able to understand the nature of the study and to sign a written consent form Exclusion Criteria: Gastro-intestinal surgery that may modify or decrease the intestinal absorption of nutrient and experimental product Serious traumatism in the last 3 months Heavy surgery operation in the last 3 months Non-controlled evolutive disease Drug or medication abuse in the last 2 years History of non-compliance in previous studies Regular consumption of similar ingredients or food supplements compared to experimental product in the past 3 months Any medical problem or trouble identified by the investigator that could alter the capacity of the volunteer to end the study Any drug medication that could mask, decrease or interfere experimental product efficacy Surgery operation planned during the year Breastfeeding, pregnant women Known allergies to one of the ingredients entering in the composition of the experimental product Severe liver and renal failure Actual participation to another clinical trial

Sites / Locations

  • Clinica Castello 68Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Experimental Stemregen

Arm Description

Experimental product encapsulated will be consumed orally with a glass of water. Six capsules per day will be consumed daily for 6 months.

Outcomes

Primary Outcome Measures

Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Secondary Outcome Measures

Parkinson's Disease (PD) symptoms: Change from Baseline
UPDRS questionnaire which represents a validated and standardized questionnaire for PD diagnostic and disease progression evaluation: 0=normal - 4= Severe
Quality of Life Assessed by the Parkinson's Disease
Modified SF-36 quality of life assessment from Dr Gitte Jensen used in several clinical studies at NIS labs clinical center, Oregon USA, result from excellent to Terrible
Parkinson's Disease (PD) symptoms: Change
Schwab and England activities of daily living activities scales from 0% to 100%

Full Information

First Posted
January 11, 2023
Last Updated
January 22, 2023
Sponsor
Sociedad Española de Medicina Regenerativa y Terapia Celular
search

1. Study Identification

Unique Protocol Identification Number
NCT05699694
Brief Title
Clinical Study on the Efficacy of Natural Stem Cell Mobilizers on Parkinson Disease
Official Title
Open-labeled Pilot Study on the Efficacy of a New Food Supplement Composed of Natural Stem Cell Mobilizers for the Improvement of Motor Performance and Quality of Life in Parkinsonian Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 5, 2023 (Actual)
Primary Completion Date
August 6, 2023 (Anticipated)
Study Completion Date
October 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sociedad Española de Medicina Regenerativa y Terapia Celular

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Parkinson's disease is defined as the progressive loss or deterioration of dopaminergic neurons, Treatment approaches to maintain the normal dopamine level that include medication, surgery, cell therapy supplementation of L-Dihydroxyphenylalanine (L-Dopa), a precursor of dopamina, Stem cells from bone marrow can be mobilized according to the need of repair of the tissue. Suggested use of the food supplement actually sold in the USA and in Europe: Take two capsules, 1 to 3 times per day with a glass of water. Increase the Stem Cell circulating in the peripheral blood.
Detailed Description
Parkinson's disease is defined as the progressive loss or deterioration of dopaminergic neurons in Substantia Nigra (SN) of the brain. These cells normally produce dopamine which acts like a messenger for normal muscular movement. Having less quantity of dopamine in the synaptic cleft due to the loss of neural cells, symptoms become apparent. Neuroinflammation and oxidative stress are involved. Treatment approaches to maintain the normal dopamine level that include medication, surgery, cell therapy supplementation of L-Dihydroxyphenylalanine (L-Dopa), a precursor of dopamine, in the form of Levodopa and/or Carbidopa, has been available for PD therapy for 50 years. Stem cells constitute the repair system of the body. Stem cells from bone marrow can be mobilized according to the need of repair of the tissue. Suggested use of the food supplement actually sold in the USA and Europe: Take two capsules, 1 to 3 times per day with a glass of water. All raw materials are food grade. All extracts are water or ethanolic extracts, which are authorized solvents for dietary supplements in the USA and EU. All ingredients are compliant with US and EU contaminants regulation (microbiological profile, heavy metals, pesticides) especially EU pharmacopeia, the product shows to increase Stem Cell circulation in peripheral blood.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental Stemregen
Arm Type
Experimental
Arm Description
Experimental product encapsulated will be consumed orally with a glass of water. Six capsules per day will be consumed daily for 6 months.
Intervention Type
Dietary Supplement
Intervention Name(s)
StemRegen product
Intervention Description
Products will be consumed orally in capsules with a glass of water. Six capsules per day will be consumed daily for 6 month. Two main administration schedules are possible: Two in the morning, 2 at noon, and 2 in the evening at each meal depending on individual habits of the volunteers to reduce non-compliance.
Primary Outcome Measure Information:
Title
Adverse Events
Description
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Parkinson's Disease (PD) symptoms: Change from Baseline
Description
UPDRS questionnaire which represents a validated and standardized questionnaire for PD diagnostic and disease progression evaluation: 0=normal - 4= Severe
Time Frame
6 months
Title
Quality of Life Assessed by the Parkinson's Disease
Description
Modified SF-36 quality of life assessment from Dr Gitte Jensen used in several clinical studies at NIS labs clinical center, Oregon USA, result from excellent to Terrible
Time Frame
6 Months
Title
Parkinson's Disease (PD) symptoms: Change
Description
Schwab and England activities of daily living activities scales from 0% to 100%
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults from both genders Diagnosed by neurologist or qualified health care practitioner with PD for 5 years or more Stabilized symptomatic treatment for PD for more than 3 months Age: over 21 years old Volunteers able to understand the nature of the study and to sign a written consent form Exclusion Criteria: Gastro-intestinal surgery that may modify or decrease the intestinal absorption of nutrient and experimental product Serious traumatism in the last 3 months Heavy surgery operation in the last 3 months Non-controlled evolutive disease Drug or medication abuse in the last 2 years History of non-compliance in previous studies Regular consumption of similar ingredients or food supplements compared to experimental product in the past 3 months Any medical problem or trouble identified by the investigator that could alter the capacity of the volunteer to end the study Any drug medication that could mask, decrease or interfere experimental product efficacy Surgery operation planned during the year Breastfeeding, pregnant women Known allergies to one of the ingredients entering in the composition of the experimental product Severe liver and renal failure Actual participation to another clinical trial
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Miguel G Garber, MD
Phone
34 628766753
Email
mggarber@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Felix Pedrero, MD
Phone
34 622411766
Email
consulta@doctorpedrero.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miguel G Garber, MD
Organizational Affiliation
Healthy Longevity Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Felix Pedrero Ramallo, MD
Organizational Affiliation
Clinica Castello 68
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christian Drapeou, PhD
Organizational Affiliation
Kalyagen
Official's Role
Study Director
Facility Information:
Facility Name
Clinica Castello 68
City
Madrid
ZIP/Postal Code
28001
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miguel G Garber, MD
Phone
628766753
Email
mggarber@gmail.com
First Name & Middle Initial & Last Name & Degree
Adriana Ruiz Castro
Phone
626554939
Email
larc32@hotmail.com

12. IPD Sharing Statement

Learn more about this trial

Clinical Study on the Efficacy of Natural Stem Cell Mobilizers on Parkinson Disease

We'll reach out to this number within 24 hrs